Gaurav Pathria

Gaurav Pathria

Auto-generated profile, based on publicly available information

Gaurav Pathria

Genentech Inc., South San Francisco, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2018 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
GPGaurav Pathria
Gaurav Pathria
DSDavid A Scott
David A Scott
YFYongmei Feng
Yongmei Feng
JLJoo Sang Lee
Joo Sang Lee
YFYu Fujita
Yu Fujita
ZRZe'EV A Ronai
Ze'EV A Ronai

18 November 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
GPGaurav Pathria
Gaurav Pathria
JLJoo Sang Lee
Joo Sang Lee
EHErez Hasnis
Erez Hasnis
KTKristofferson Tandoc
Kristofferson Tandoc
DSDavid A. Scott
David A. Scott
ZRZe’eV A. Ronai
Ze’eV A. Ronai

8 September 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NSNicole M. Sodir
Nicole M. Sodir
GPGaurav Pathria
Gaurav Pathria
JAJoanne I. Adamkewicz
Joanne I. Adamkewicz
EKElizabeth H. Kelley
Elizabeth H. Kelley
JSJawahar Sudhamsu
Jawahar Sudhamsu
DMDanilo Maddalo
Danilo Maddalo
The protein phosphatase SHP2/PTPN11 has been reported to be a key modulator of proliferative pathways in a wide range of malignancies. Intriguingly, SHP2 has also been described as a critical regulator of the tumor microenvironment. Based on this evidence SHP2 is considered a multifaceted target in cancer, spurring the notion that the development of direct inhibitors of SHP2 would provide the twofold benefit of tumor intrinsic and extrinsic inhibition. In this review, we will discuss the role of SHP2 in cancer and the tumor microenvironment, and the clinical strategies in which SHP2 inhibitors are leveraged as combination agents to improve therapeutic response. Significance: The SHP2 phosphatase functions as a pleiotropic factor, and its inhibition not only hinders tumor growth but also reshapes the tumor microenvironment. Although their single-agent activity may be limited, SHP2 inhibitors hold the potential of being key combination agents to enhance the depth and the durability of tumor response to therapy.

1 January 2021 in Cell Metabolism
Verified
Journal Article
Closed access
GPGaurav Pathria
Gaurav Pathria
ZRZe’eV A. Ronai
Ze’eV A. Ronai

8 February 2021 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
GPGaurav Pathria
Gaurav Pathria
SVSachin Verma
Sachin Verma
JYJun Yin
Jun Yin
DSDavid A Scott
David A Scott
ZRZe’EV A Ronai
Ze’EV A Ronai

25 February 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YFYongmei Feng
Yongmei Feng
GPGaurav Pathria
Gaurav Pathria
SHSusanne Heynen-Genel
Susanne Heynen-Genel
MJMichael Jackson
Michael Jackson
BJBrian James
Brian James
ZRZe'Ev A. Ronai
Ze'Ev A. Ronai
A key hallmark of cancer, altered metabolism, is central to cancer pathogenesis and therapy resistance. Robust glutamine metabolism is among cellular processes regulating tumor progression and responsiveness to therapy in a number of cancers, including melanoma and breast cancer. Among mechanisms underlying the increase in glutamine metabolism in tumors is enhanced glutamine uptake mediated by the glutamine transporters, with SLC1A5 (also known as ASCT2) shown to play a predominant role. Correspondingly, increased SLC1A5 expression coincides with poorer survival in patients with breast cancer and melanoma. Therefore, we performed an image-based screen to identify small molecules that are able to prevent the localization of SLC1A5 to the plasma membrane without impacting cell shape. From 7,000 small molecules, nine were selected as hits, of which one (IMD-0354) qualified for further detailed functional assessment. IMD-0354 was confirmed as a potent inhibitor of glutamine uptake that attained sustained low intracellular glutamine levels. Concomitant with its inhibition of glutamine uptake, IMD-0354 attenuated mTOR signaling, suppressed two- and three-dimensional growth of melanoma cells, and induced cell-cycle arrest, autophagy, and apoptosis. Pronounced effect of IMD-0354 was observed in different tumor-derived cell lines, compared with nontransformed cells. RNA-sequencing analysis identified the unfolded protein response, cell cycle, and response (DNA damage response pathways) to be affected by IMD-0354. Combination of IMD-0354 with GLS1 or LDHA inhibitors enhanced melanoma cell death. In vivo, IMD-0354 suppressed melanoma growth in a xenograft model. As a modulator of glutamine metabolism, IMD-0354 may serve as an important therapeutic and experimental tool that deserves further examination.